Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Genomic Health Inc (NASDAQ: GHDX) acted responsibly on behalf of investors’ profitability in the planned $2.8 billion sale to Exact Sciences Corporation.

On July 29, 2019, Genomic Health Inc (NASDAQ: GHDX) and Exact Sciences Corporation announced that they had entered into a merger agreement. Under the terms of the merger agreement, Genomic shareholders will receive only $27.50 in cash and $44.50 in Exact Sciences stock for each share of Genomic stock they own.

Based in Redwood City, California, and founded in 2000 Genomic Health Inc provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally.

The investigation focuses on whether NASDAQ: GHDX investors received the highest price and whether the directors of Genomic Health Inc acted in the best interest of Genomic Health Inc company and its shareholders.   

If you purchased Genomic Health Inc (NASDAQ: GHDX) prior to July 29, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185